SBP-302

N/A

Report date: 2023/03/05 18:10:36

NME

Base Information

Drug NameSBP-302

Drug Alias NameSBP-302

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionUpdating

TargetsUpdating

Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSpark Biopharma Inc

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Inactive IndicationsN/A

ATC CodeN/A